Interaction of RAS activation and lipid disorders accelerates the progression of glomerulosclerosis

International Journal of Medical Sciences

Volumn 10, Issue 12, 2013, Pages 1615-1624

  Ma, Kun Ling ^a   Ni, Jie ^a   Wang, Chang Xian ^a   Liu, Jing ^a   Zhang, Yang ^a   Wu, Yu ^a   Lv, Lin Li ^a   Ruan, Xiong Zhong ^b   Liu, Bi Cheng ^a  

^a MEDICAL SCHOOL OF SOUTHEAST UNIVERSITY   (China)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Extracellular matrix; Glomerulosclerosis; Lipid disorder; Low density lipoprotein receptor; Renin angiotensin system

Indexed keywords

25 HYDROXYCHOLESTEROL; ALPHA SMOOTH MUSCLE ACTIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN II; ANGIOTENSINOGEN; CELL PROTEIN; CHOLESTEROL; COLLAGEN; DIPEPTIDYL CARBOXYPEPTIDASE; FAT DROPLET; FIBRONECTIN; LOW DENSITY LIPOPROTEIN RECEPTOR; MESSENGER RNA; RENIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 2; STEROL REGULATORY ELEMENT BINDING PROTEIN CLEAVAGE ACTIVATING PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; DISEASE COURSE; DYSLIPIDEMIA; ENDOPLASMIC RETICULUM; EXTRACELLULAR MATRIX; FEEDBACK SYSTEM; GENE EXPRESSION; GLOMERULOSCLEROSIS; GOLGI COMPLEX; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; LIPID STORAGE; MESANGIUM CELL; PATHOGENESIS; PROTEIN EXPRESSION; PROTEIN TRANSPORT; REAL TIME POLYMERASE CHAIN REACTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; WESTERN BLOTTING;

EXTRACELLULAR MATRIX; GLOMERULOSCLEROSIS; LIPID DISORDER; LOW-DENSITY LIPOPROTEIN RECEPTOR; RENIN-ANGIOTENSIN SYSTEM;

ANGIOTENSIN II; CHOLESTEROL; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; ENDOPLASMIC RETICULUM; GENE EXPRESSION REGULATION; HUMANS; HYDROXYCHOLESTEROLS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LIPID METABOLISM; MEMBRANE PROTEINS; MESANGIAL CELLS; RAS PROTEINS; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTORS, LIPOPROTEIN; RENIN-ANGIOTENSIN SYSTEM; STEROL REGULATORY ELEMENT BINDING PROTEIN 2; STEROL REGULATORY ELEMENT BINDING PROTEINS;

EID: 84886068167     PISSN: 14491907     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijms.6635     Document Type: Article

References (31)

1. Daskalakis N, Winn MP. Focal and segmental glomerulosclerosis. Cell Mol Life Sci 2006; 63(21):2506-2511.
2. Pozzi A, Voziyan PA, Hudson BG, Zent R. Regulation of matrix synthesis, remodeling and accumulation in glomerulosclerosis. Curr Pharm Des 2009; 15(12):1318-1333.
3. Mattana J, Kochlatyi S, Gibbons N. Metal-catalyzed oxidation of extracellular matrix proteins promotes human mesangial cell apoptosis and is associated with enhanced expression of Bax and caspase activation. Biochem Biophys Res Commun 2002; 292(3):652-658.
4. Hua P, Feng W, Rezonzew G, Chumley P, Jaimes EA. The transcription factor ETS-1 regulates angiotensin II-stimulated fibronectin production in mesangial cells. Am J Physiol Renal Physiol 2012; 302(11):F1418-F1429.
5. Keane WF. The role of lipids in renal disease: future challenges. Kidney Int Suppl 2000; 75:S27-S31.
6. Singh BK, Mehta JL. Interactions between the renin-angiotensin system and dyslipidemia: relevance in atherogenesis and therapy of coronary heart disease. Indian Heart J 2001; 53(4):511-518.
7. Singh BM, Mehta JL. Interactions between the renin-angiotensin system and dyslipidemia: relevance in the therapy of hypertension and coronary heart disease. Arch Intern Med 2003; 163(11):1296-1304.
8. Catar RA, Muller G, Heidler J, Schmitz G, Bornstein SR, Morawietz H. Low-density lipoproteins induce the renin-angiotensin system and their receptors in human endothelial cells. Horm Metab Res 2007; 39(11):801-805.
9. Wang X, Phillips MI, Mehta JL. LOX-1 and angiotensin receptors, and their interplay. Cardiovasc Drugs Ther 2011; 25(5):401-417.
10. Gamble W, Vaughan M, Kruth HS, Avigan J. Procedure for determination of free and total cholesterol in micro-or nanogram amounts suitable for studies with cultured cells. J Lipid Res 1978; 19(8):1068-1070.
11. Solini A, Rossi C, Santini E, Madec S, Salvati A, Ferrannini E. Angiotensin-II and rosuvastatin influence matrix remodeling in human mesangial cells via metalloproteinase modulation. J Hypertens 2011; 29(10):1930-1939.
12. Wang Z, Jiang T, Li J, Proctor G, McManaman JL, Lucia S, et al. Regulation of renal lipid metabolism, lipid accumulation, and glomerulosclerosis in FVBdb/db mice with type 2 diabetes. Diabetes 2005; 54(8):2328-2335.
13. Sasatomi Y, Tada M, Uesugi N, Hisano S, Takebayashi S. Obesity associated with hypertension or hyperlipidemia accelerates renal damage. Pathobiology 2001; 69(2):113-118.
14. Ni J, Ma KL, Wang CX, Liu J, Zhang Y, Lv LL, et al. Activation of renin-angiotensin system is involved in dyslipidemia-mediated renal injuries in apolipoprotein E knockout mice and HK-2 cells. Lipids Health Dis 2013; 12(1):49.
15. Kostapanos MS, Liberopoulos EN, Elisaf MS. Statin pleiotropy against renal injury. J Cardiometab Syndr 2009; 4(1):E4-E9.
16. Oite T. Exploring the mechanisms of renoprotection against progressive glomerulosclerosis. Proc Jpn Acad Ser B Phys Biol Sci 2011; 87(3):81-90.
17. Hongo M, Ishizaka N, Furuta K, Yahagi N, Saito K, Sakurai R, et al. Administration of angiotensin II, but not catecholamines, induces accumulation of lipids in the rat heart. Eur J Pharmacol 2009; 604(1-3):87-92.
18. Ishizaka N, Hongo M, Sakamoto A, Saito K, Furuta K, Koike K. Liver lipid content is reduced in rat given 7-day administration of angiotensin II. J Renin Angiotensin Aldosterone Syst 2011; 12(4):462-468.
19. Saito K, Ishizaka N, Hara M, Matsuzaki G, Sata M, Mori I, et al. Lipid accumulation and transforming growth factor-beta upregulation in the kidneys of rats administered angiotensin II. Hypertension 2005; 46(5):1180-1185.
20. Abrass CK. Cellular lipid metabolism and the role of lipids in progressive renal disease. Am J Nephrol 2004; 24(1):46-53.
21. Pilon A, Martin G, Bultel-Brienne S, Junquero D, Delhon A, Fruchart JC, et al. Regulation of the scavenger receptor BI and the LDL receptor by activators of aldosterone production, angiotensin II and PMA, in the human NCI-H295R adrenocortical cell line. Biochim Biophys Acta 2003; 1631(3):218-228.
22. Hu C, Kang BY, Megyesi J, Kaushal GP, Safirstein RL, Mehta JL. Deletion of LOX-1 attenuates renal injury following angiotensin II infusion. Kidney Int 2009; 76(5):521-527.
23. Sendra J, Llorente-Cortes V, Costales P, Huesca-Gomez C, Badimon L. Angiotensin II upregulates LDL receptor-related protein (LRP1) expression in the vascular wall: a new pro-atherogenic mechanism of hypertension. Cardiovasc Res 2008; 78(3):581-589.
24. Kumar R, Boim MA. Diversity of pathways for intracellular angiotensin II synthesis. Curr Opin Nephrol Hypertens 2009; 18(1):33-39.
25. Nickenig G, Sachinidis A, Michaelsen F, Bohm M, Seewald S, Vetter H. Upregulation of vascular angiotensin II receptor gene expression by low-density lipoprotein in vascular smooth muscle cells. Circulation 1997; 95(2):473-478.
26. Li D, Saldeen T, Romeo F, Mehta JL. Oxidized LDL upregulates angiotensin II type 1 receptor expression in cultured human coronary artery endothelial cells: the potential role of transcription factor NF-kappaB. Circulation 2000; 102(16):1970-1976.
27. Park SY, Song CY, Kim BC, Hong HK, Lee HS. Angiotensin II mediates LDL-induced superoxide generation in mesangial cells. Am J Physiol Renal Physiol 2003; 285(5):F909-F915.
28. Wenzel UO, Krebs C, Benndorf R. The angiotensin II type 2 receptor in renal disease. J Renin Angiotensin Aldosterone Syst 2010; 11(1):37-41.
29. Wolf G, Wenzel U, Burns KD, Harris RC, Stahl RA, Thaiss F. Angiotensin II activates nuclear transcription factor-kappaB through AT1 and AT2 receptors. Kidney Int 2002; 61(6):1986-1995.
30. Siragy HM. AT1 and AT2 receptor in the kidney: role in health and disease. Semin Nephrol 2004; 24(2):93-100.
31. Yang Y, Zhang SY, Sich M, Beziau A, van den Heuvel LP, Gubler MC. Glomerular extracellular matrix and growth factors in diffuse mesangial sclerosis. Pediatr Nephrol 2001; 16(5):429-438.